X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AJANTA PHARMA LTD. Fact Sheet - Equitymaster
Investing in India? Get Equitymaster Research  

AJANTA PHARMA LTD.  (AJPH)


Here is the latest financial fact sheet of AJANTA PHARMA. For more details, see the AJANTA PHARMA quarterly results and AJANTA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
 
ajanta pharma - 1 Year Stock Price Chart
Loading...

 Price History
    Price Rs 1,836.3       No. of shares m 87.95
    Mkt Cap Rs m 161,503       % ch % 0.3
    Vol '000 5.1       % ch week % 4.2
    P/E X 32.4       % ch 1-mth % 7.8
    P/CF X 36.2       % ch 12-mth % 30.9
    EPS (TTM) Rs 56.8       52 week H/L Rs 2,150.0/1,311.8
(As on Mar 23, 2017 (Close)) »  Best Performing pharmaceuticals Stocks

Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!
 Financials

* Results Consolidated
No. of Months
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
  EQUITY SHARE DATA
High Rs4926981,1777791,720 
Low Rs2012316252991,103 
Sales per share (Unadj.) Rs571.2392.4340.8166.1194.6 
Earnings per share (Unadj.) Rs65.247.366.034.945.2 
Diluted earnings per shareRs8.812.726.635.245.6 
Cash flow per share (Unadj.) Rs92.061.778.340.850.3 
Dividends per share (Unadj.) Rs7.506.2510.006.008.00 
Adj. dividends per shareRs1.011.694.036.058.07 
Dividend yield (eoy) %2.21.31.11.10.6 
Book value per share (Unadj.) Rs251.3165.9167.394.8132.0 
Adj. book value per shareRs33.944.767.595.6133.3 
Shares outstanding (eoy) m11.8623.7235.4688.7188.77 
Bonus/Rights/Conversions  -FV5B1:2,ESOSFV2- 
Price / Sales ratio x0.61.22.63.27.3 
Avg P/E ratio x5.39.813.715.431.2 
P/CF ratio (eoy) x3.87.511.513.228.1 
Price / Book Value ratio x1.42.85.45.710.7 
Dividend payout %11.513.215.217.217.7 
Avg Mkt Cap Rs m4,10911,02131,95147,797125,299 
No. of employees `000NANANANANA 
Total wages/salary Rs m9381,2321,5702,0062,570 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
  INCOME DATA
Net Sales Rs m6,7749,30812,08314,73617,275 
Other income Rs m6256137168166 
Total revenues Rs m6,8369,36412,22114,90417,442 
Gross profit Rs m1,3202,2453,6885,0525,807 
Depreciation Rs m319342439516451 
Interest Rs m154191875949 
Profit before tax Rs m9101,7683,2994,6455,474 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m000-850 
Tax Rs m1376479601,4621,460 
Profit after tax Rs m7731,1212,3393,0994,014 
Gross profit margin %19.524.130.534.333.6 
Effective tax rate %15.136.629.131.526.7 
Net profit margin %11.412.019.421.023.2 
  BALANCE SHEET DATA
Current assets Rs m3,3973,6905,2016,3347,639 
Current liabilities Rs m2,5022,2232,7542,4962,715 
Net working cap to sales %13.215.820.226.028.5 
Current ratio x1.41.71.92.52.8 
Inventory Days Days9058473943 
Debtors Days Days7659616479 
Net fixed assets Rs m2,4862,8513,7294,5836,914 
Share capital Rs m118118177177177 
"Free" reserves Rs m2,8253,7745,6508,18611,442 
Net worth Rs m2,9803,9345,9338,41111,721 
Long term debt Rs m761733523333149 
Total assets Rs m6,4887,1829,49411,46414,814 
Interest coverage x6.910.238.879.5112.9 
Debt to equity ratio x0.30.20.100 
Sales to assets ratio x1.01.31.31.31.2 
Return on assets %14.318.325.627.527.4 
Return on equity %25.928.539.436.834.2 
Return on capital %28.442.052.452.846.5 
Exports to sales %50.654.454.754.755.1 
Imports to sales %5.65.65.04.46.0 
Exports (fob) Rs m3,4275,0676,6068,0629,527 
Imports (cif) Rs m3775246026531,038 
Fx inflow Rs m3,5485,3336,8968,49410,422 
Fx outflow Rs m6809351,1681,2471,678 
Net fx Rs m2,8684,3995,7287,2478,744 
  CASH FLOW
From Operations Rs m 704 2,343 2,124 2,794 3,264 
From Investments Rs m -531 -1,037 -1,878 -1,584 -2,093 
From Financial Activity Rs m -128 -1,045 -201 -1,052 -1,186 
Net Cashflow Rs m 44 261 45 159 -15 
* Results Consolidated Source: Company Annual Reports, Regulatory Filings, Equitymaster »  Historical quarterly results for ajanta pharma ltd.

 Share Holding
Indian Promoters : 73.8%
Foreign collaborators : 0.0%
Indian inst/Mut Fund : 1.6%
FIIs : 7.6%
ADR/GDR : 0.0%
Free float : 17.0%
Shareholders : 20,968
Pledged promoter(s) holding : 4.4%
 Company Information
Top
    REGD OFF: Ajanta House, Charkop, Kandivli (W), Mumbai - 400 067
    E-MAIL: deodatta.pandit@ajantapharma.com     WEB: www.ajantapharma.com
    TELEPHONE: (022) 66061000     FAX: (022) 6606 1200
    SECTOR: PHARMACEUTICALS     GROUP: MISCELLANEOUS
    TR AGENT: Link Intime India, C13, Pannalal Silk Mills Compd., LBS Marg, Mumbai-78
    AUDITOR: Kapoor & Parekh Assoc.
CHM: Mannalal B. Agrawal COMP SEC: Gaurang Shah YEAR OF INC: 1979 BSE CODE: 532331 FV (Rs): 5 DIV YIELD (%): 0.4

More pharmaceuticals Company Fact Sheets:   SUN PHARMAPLETHICO PHARMAJ.B.CHEMICALSUNICHEM LABPIRAMAL ENTERPRISES


Today's Market

Sensex Closes Firm; NTPC Surges 2.3%(Closing)

Indian share markets continued to trade higher owing to firm global cues with energy stocks leading the gains, while financial stocks and auto stocks bounced back.

Views on news

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Bluechips Have 60% Chance Of Losing Money At Current Levels. But a Small Group Won't...(The 5 Minute Wrapup)

Mar 17, 2017

The trend that makes a select group of bluechip stocks inherently safer even at peak index valuations.

As Digital Transactions Fall, Indians Are Going Back to Cash(Vivek Kaul's Diary)

Mar 16, 2017

Digital transactions have fallen since December 2016 both in value and volume terms.

Stock Markets and Gold Rally, Dollar Tumbles(Chart Of The Day)

Mar 16, 2017

Markets are moving up even after the fed interest rate hike.

Why You Should Try SCOREFASTTM Right Now(Daily Profit Hunter)

Mar 10, 2017

Asad Dossani discusses why SCOREFASTM will be a successful trading strategy

4 Things To Watch Out For After Modi's Landslide Win In UP Polls(Outside View)

Mar 15, 2017

PersonalFN explains why you need to wary while investing in equities despite Modi's UP win.

More

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AJANTA PHARMA

AJANTA PHARMA - MYLAN COMPARISON

Compare Company With Charts

COMPARE AJANTA PHARMA WITH

MARKET STATS